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Surgical Standards for Management of the Axilla in Breast
Cancer Clinical Trials with Pathological Complete Response
Endpoint
Judy C. Boughey1, Michael D. Alvarado2, Rachael B. Lancaster3, W. Fraser Symmans4, Rita Mukhtar2, Jasmine M. Wong2,
Cheryl A. Ewing2, David A. Potter5, Todd M. Tuttle6, Tina J. Hieken1, Jodi M. Carter7, James W. Jakub1, Henry G. Kaplan8,
Claire L. Buchanan8, Nora T. Jaskowiak9, Husain A. Sattar10, Jeffrey Mueller10, Rita Nanda11, Claudine J. Isaacs12, Paula R. Pohlmann 12,
Filipa Lynce12, Eleni A. Tousimis12, Jay C. Zeck12, M. Catherine Lee13, Julie E. Lang 14, Paulette Mhawech-Fauceglia14, Roshni Rao15,
Bret Taback15, Constantine Godellas16, Margaret Chen15, Kevin M. Kalinsky15, Hanina Hibshoosh15, Brigid Killelea17, Tara Sanft17,
Gillian L. Hirst 2, Smita Asare18, Jeffrey B. Matthews2, Jane Perlmutter19, Laura J. Esserman2 and I-SPY 2 Investigators25
Advances in the surgical management of the axilla in patients treated with neoadjuvant chemotherapy, especially those with node
positive disease at diagnosis, have led to changes in practice and more judicious use of axillary lymph node dissection that may
minimize morbidity from surgery. However, there is still significant confusion about how to optimally manage the axilla, resulting in
variation among practices. From the viewpoint of drug development, assessment of response to neoadjuvant chemotherapy
remains paramount and appropriate assessment of residual disease—the primary endpoint of many drug therapy trials in the
neoadjuvant setting—is critical. Therefore decreasing the variability, especially in a multicenter clinical trial setting, and establishing
a minimum standard to ensure consistency in clinical trial data, without mandating axillary lymph node dissection, for all patients is
necessary. The key elements which include proper staging and identification of nodal involvement at diagnosis, and appropriately
targeted management of the axilla at the time of surgical resection are presented. The following protocols have been adopted as
standard procedure by the I-SPY2 trial for management of axilla in patients with node positive disease, and present a framework for
prospective clinical trials and practice.
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INTRODUCTION
The use of neoadjuvant systemic treatment in the clinical care of
patients with breast cancer has increased dramatically over
recent years. For patients with breast cancer with high-risk
biologic features, in particular triple negative breast cancer
(TNBC) and HER2-positive breast cancer, it is becoming the
primary recommendation. The neoadjuvant setting also offers
important advantages that have enabled accelerated develop-
ment of new drugs for women with breast cancer. In 2012, the
US Food and Drug Administration (FDA) released guidance
indicating they would consider granting accelerated drug
approval on the basis of a surrogate endpoint that is reasonably
likely to predict clinical benefit. For neoadjuvant breast cancer
treatment they proposed the rate of pathological complete
response (pCR)—the complete eradication of disease—as a
surrogate.1 This validated and highlighted the importance of the
neoadjuvant setting for assessment of therapeutic response in
breast cancer. As clinical trials involving neoadjuvant systemic
therapy which include pathologic complete response as the
primary endpoint increase, standardizing the surgical manage-
ment in these trials is important in the face of evolving surgical
techniques, in particular as it relates to the management of the
axilla. Herein, we present surgical standards for management of
the axilla in patients treated with neoadjuvant chemotherapy on
clinical trials.
The definition of pCR varies across different clinical trials. Of the
three most common definitions of pCR—ypT0/is, ypT0/is ypN0,
ypT0 ypN0—those that best correlate with survival incorporate
assessment of both the breast and the lymph nodes (ypT0/is
ypN0, and ypT0 ypN0).2 Therefore, for clinical trials of novel agents
in which pCR is the primary endpoint, these definitions—the
absence of tumor in the breast as well as in the axillary lymph
nodes—are the preferred definitions, reinforcing the importance
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of accurate assessment of axillary nodes for disease after
neoadjuvant chemotherapy.
One significant advance in the surgical management of patients
treated with neoadjuvant chemotherapy is the potential to allow
less invasive surgical intervention in the axilla for those patients
who have an excellent response to neoadjuvant chemotherapy.
Staging of axillary lymph nodes has generally been performed by
sentinel lymph node (SLN) surgery. However, SLN surgery in all
settings is associated with a false negative rate (FNR). SLN in the
absence of neoadjuvant therapy is associated with a FNR of
6–11%3–6; in the setting of node-negative disease treated with
neoadjuvant chemotherapy, surgical staging of the axilla after
NAC by SLN has a similar FNR of 6–12%.7–11 Historically, in node
positive disease, ALND was recommended to ensure resection of
all nodes in level I and II of the axilla for pathologic evaluation.
However, there is now evidence from prospective clinical trials to
support the use of SLN surgery after neoadjuvant chemotherapy
for patients presenting with clinically node positive disease who
have a good clinical and imaging response.12–14
The European SENTINA trial enrolled patients with node positive
disease based on clinical examination alone (only 25% had a fine-
needle aspirate of an axillary lymph node) and required patients
to have a negative axilla sonographically after completion of NAC.
Although overall, SLN surgery had a FNR of 14.2% (32/226); when
limited to patients with greater than one SLN resected, the FNR
was 9.6% (15/156). The ACOSOG Z1071 trial enrolled 756 patients
with clinical node positive disease proven by percutaneous needle
biopsy. Of the 525 eligible patients with clinical N1 disease, where
2 or two more SLNs were resected, the FNR of SLN surgery was
12.6% (39/310). This study further showed that in the cases where
both radioactive colloid and blue dye were utilized to identify the
SLNs, the FNR was reduced to 10.8% (27/251). When immunohis-
tochemistry was performed on the SLNs, the FNR was 8.7%. In the
170 cases where a clip was placed in the positive lymph node at
diagnosis, a subset analysis showed that with resection of the
clipped node at the time of SLN surgery, the FNR was 6.8%.15 The
Canadian SN-FNAC trial enrolled a total of 153 patients and
reported a FNR of 13.3% when limiting node positive disease to
nodal metastases >0.2 mm; it was reduced to 8.4% when cases
with isolated tumor cells [N0(i+)] were assessed as node positive.
The study also showed that the FNR was lower when two or more
SLNs were resected (4.9%) and when dual tracer was utilized for
SLN identification (5.2%).
Subsequently, based on the clipped node data from the Z1071
trial, the group at MD Anderson Cancer Center adjusted their
practice to preoperatively localize and ensure resection of the
clipped node at the time of SLN surgery. They describe this as
‘targeted axillary dissection’ and reported a FNR of 2.4% with the
removal of the SLNs and the localized clipped node.16 The
Netherlands Cancer Institute has utilized a technique called “MARI
—marking the axillary lymph node with a radioactive seed” in
which the radioactive seed is placed in the lymph node at the time
of initial percutaneous biopsy prior to chemotherapy and then this
radioactive seed localized lymph node only is resected at the time
of surgery without SLN surgery. They reported a FNR of 7% (65/
70).17 Alternative methods to mark the positive node at initial
biopsy have also been explored including tattooing the node with
ink or charcoal.18,19
WHY A NEED FOR SURGICAL STANDARDS FOR AXILLARY
MANAGEMENT IN CLINICAL TRIALS?
With these advances, the surgical management of the axilla in
patients treated with NAC is increasingly varied between practices.
In the multicenter clinical trial setting, this can be problematic,
introducing an additional source of variance in outcome assess-
ment. In clinical trials with pCR as the primary endpoint evaluating
therapies for potential FDA approval, accurate assessment of the
axillary nodes after neoadjuvant chemotherapy is crucial. The
I-SPY2 trial program therefore set out to evaluate the axillary
surgery practices of surgeons at its current and prospective clinical
trial sites. A survey was distributed to the surgeons at fourteen
participating I-SPY2 sites and fifty-two surgeons at prospective
national and international I-SPY3 sites. A total of 46 responses
were collected. Survey results demonstrated a wide variation in
surgical approaches to the axilla for clinically node positive
patients treated with neoadjuvant chemotherapy who are
clinically node negative at the time of surgery (Fig. 1).
Routine SLN surgery with the possibility of ALND depending on
pathology was reported by 17.4% (N= 8), while most surgeons
(N= 22, 47.9%) report offering SLN surgery with the possibility of
omitting ALND on a case-by-case or selective basis. Routine ALND
was recommended by 17.4% (N= 8). Enrollment in a clinical trial
on axillary management was choosen by seven surgeons (15%).
Additionally, when surveyed regarding their approach to SLN
surgery, surgeons reported differing protocols for performing SLN
surgery in the setting of a patient who was clinically node positive
treated with NAC. In the 39 surgeons who reported performing
SLN surgery in this setting, most (N= 21, 53.8%) reported their
protocol for identifying the SLNs utilized dual mapping agents
with removal of the previous clipped node(s) and removal of 2–3
nodes. Other methods utilized included dual mapping agents with
or without removal of previously clipped nodes with a minimum
of 2–3 nodes (N= 10, 25.6%), single agent mapping with removal
of the clipped node(s) with a minimum of 2–3 lymph nodes (N=
7, 17.9%), and single agent mapping with or without the removal
of the clipped nodes with a minimum of 2–3 nodes (N= 1, 2.6%).
Therefore, in the setting of clinical trials evaluating response to
systemic therapy, given the importance of accurate staging of the
axillary lymph nodes along with optimizing the clinical manage-
ment of patient care and avoiding over-treatment and invasive
axillary surgery, there is a need to standardize the optimal surgical
management of the axilla for patients treated with neoadjuvant
chemotherapy on prospective clinical trials evaluating pCR as a
primary endpoint. The multidisciplinary team from the I-SPY2
clinical trial leadership along with their principal investigators
including surgeons, medical oncologist, and pathologist across
sites have developed a recommended minimum standard, as
follows, for surgical management of the axilla in patients with
clinically node positive disease treated with neoadjuvant che-
motherapy. The goal of these guidelines is to set a standard that
surgeons adhere to when treating patients on a clinical trial with a
pCR primary endpoint and can also be used to inform manage-
ment outside of a clinical trial.
Fig. 1 Current methods of management of axilla at the time of
surgery in node positive patients who undergo NAC, as reported by
participating surgeons surveyed in the I-SPY2 trial
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I-SPY2 RECOMMENDED STANDARDS
The following protocols have been adopted as standard minimum
procedure by the I-SPY2 trial (NCT01042379), for management of
axilla in patients with node positive disease (see Fig. 2).
INITIAL DIAGNOSIS (BASELINE)
At initial diagnosis with breast cancer, prior to chemotherapy,
placement of a clip at the primary tumor site at the time of
diagnosis is standard for all patients treated with neoadjuvant
systemic therapy. Additionally, evaluation should include doc-
umentation of the clinical nodal status by physical examination
and axillary ultrasound. Cases with sonographically abnormal
lymph nodes (cortex > 3mm) should undergo percutaneous
needle biopsy (fine needle aspiration or core needle biopsy) of
the most abnormal lymph node, for cytologic or histologic
evaluation for the presence of metastatic disease. Placement of
a clip in the biopsy-proven positive node is strongly recom-
mended, to aid identification of this node at surgery after
completion of chemotherapy. Clip placement can be performed
at the time of fine needle aspiration biopsy or core needle biopsy
of the lymph node or at a subsequent time point if needed. If
multiple nodes are biopsied, the most abnormal appearing node
should be clipped. Placement of the clip in the hilum of the lymph
node can avoid potential issues with clip migration during
response to chemotherapy. Surgical staging of the axilla must
occur after neoadjuvant chemotherapy. Axillary surgery before
neoadjuvant chemotherapy loses the ability to assess response to
therapy and to document the presence or absence of residual
disease, therefore in trials with pCR as the primary endpoint all
axillary surgery must occur after completion of neoadjuvant
chemotherapy.
SURGICAL MANAGEMENT AFTER NEOADJUVANT THERAPY
Surgery for resection of the breast primary and staging of the
axillary nodes should be performed no earlier than 3 weeks after
last dose of cytotoxic chemotherapy and no later than 12 weeks
after the last dose of cytotoxic chemotherapy. All patients must
undergo resection of the site of primary disease in the breast by
either breast conservation or mastectomy. In cases with complete
imaging response, surgical resection is still required to assess for
residual disease at the site of the index tumor as this is a critical
component of response assessment for evaluation of new drugs.
The resection is guided by the residual tumor seen on imaging in
relation to the clip placed at diagnosis. If the tumor is no longer
present on imaging, the entire surgical bed does not need to be
removed, and thus placement of multiple clips to map out the
extent of a single tumor at presentation is discouraged. The area
of the tumor must be sampled to confirm pCR, and the clip serves
as guidance for such a resection. When the original tumor is
diffuse and hormone receptor positive, it is more likely that
scattered disease may be present over the area of the tumor
bed,20 and this may impact the approach to surgical resection.
The American Joint Committee on Cancer ypT catgeory is based
on the size of the largest contiguous focus of residual viable
tumor, excluding areas of fibrotic tumor bed. A more compre-
hensive method of pathological evaluation of response after
neoadjuvant chemotherapy is the residual cancer burden (RCB),
which accounts for intervening fibrosis by incorporating the
largest two-dimensional area of extent of residual invasive cancer
and the percent of that area containing cancer cells, percentage of
cancer that is in situ disease, and the extent of nodal involvement
by the number of involved lymph nodes, and size of largest
diameter of metastasis in the lymph nodes.21 I-SPY2 uses the
methodology of mapping the histopathologic sections to the
macroscopic findings as its standard procedure to accurately
determine the extent of residual disease for ypStage and RCB, to
maintain standardized pathology procedures across clinical sites
and minimize the chance of missing residual disease.
AXILLARY SURGICAL MANAGEMENT AFTER NEOADJUVANT
THERAPY
Clinically node negative disease
Patients with no abnormal lymph nodes by examination and
those whose needle biopsy is negative are classified as clinically
node negative (cN0). In these cases, axillary surgical staging after
neoadjuvant chemotherapy with SLN surgery is strongly recom-
mended. Axillary dissection is permitted in cases with failure to
identify SLNs. Use of dual tracer mapping (a blue dye and a
radiolabeled agent or magnetic tracer) is recommended and
resection of at least two SLNs is recommended. Careful evaluation
of the axilla should be performed, including palpation and
resection of all blue nodes and all radioactive nodes with counts
>10% of the hottest node. All palpable nodes that are suspicious
should also be resected.
Fig. 2 Recommended standards for axillary management in clinical
trials of neoadjuvant therapy for breast cancer where pCR is the
primary endpoint, for clinical node negative and clinical node
positive disease at time of diagnosis
Surgical standards for management of the axilla
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Clinically node positive disease at diagnosis
Those patients with positive needle biopsy at diagnosis (prior to
chemotherapy) are classified as clinically node positive [cN1-3(f)].
Additionally, in patients with abnormal nodes by palpation and
those with a positive PET CT or equivalent staging exam,
percutaneous needle biopsy for histologic/cytologic evaluation is
strongly recommended, with placement of a clip in the positive
node. Although PET-positive axillary nodes are often assumed to
be involved, biopsy and placement of a clip in those nodes is
recommended as it enables targeting of the node for removal and
evaluation after neoadjuvant chemotherapy. cN1 disease includes
patients without matted nodes, even if several/multiple nodes
appear abnormal on ultrasound or MRI. cN2 requires clinically
fixed or matted nodes on examination or clinically or imaging
detected internal mammary nodal involvement.
After completion of neoadjuvant chemotherapy, surgical
management may include either SLN surgery or ALND. If SLN
surgery is performed, dual tracer mapping is required (with the
use of blue agent as well as a radiolabeled agent or MagTrace)
along with careful evaluation of the axilla, including palpation,
resection of radioactive nodes with a count greater than 10% of
the hottest node, and resection of all blue nodes. All palpable
nodes that are suspicious should also be resected. In cases where
a clip was placed in the positive node at diagnosis, the clipped
node should be resected, and this can be achieved by any of
several different methods. The clipped node may be identified as
one of the SLNs (this will occur in approximately 75% of cases).
Intraoperative palpation or ultrasound can be used to help find
the clipped node, or alternatively, preoperative localization of the
clipped node with a wire or radioactive or localizable seed or
tattoo to ensure its identification can be performed. Direct
visualization of the clip, specimen radiography or intraoperative
pathologic assessment is necessary to confirm that the clipped
node has been resected and should be documented. Pathology is
recommended to report the histologic findings of the clipped
node specifically in their report. If the clipped node is not resected,
then ALND is strongly recommended. In cases with node positive
disease at presentation, where a clip was not placed in the
positive node, pathology is recommended to comment on the
presence or absence of biopsy site changes in the SLNs. In the
absence of a clip, a minimum of two SLNs are required to be
resected after completion of neoadjuvant chemotherapy and if
this is not achieved ALND is required.
Positive SLN
In all patients (cN0 or cN+) with a positive SLN after neoadjuvant
chemotherapy, the standard recommendation is ALND. However,
the additional management of the axilla (ALND and/or axillary
radiation) is at the discretion of the treating multidisciplinary
team. For clinical trials such as I-SPY2, where the primary endpoint
is pCR versus no pCR, in cases where any of the SLNs are positive,
the patient will be classified as having RCB class 2 (RCB 2) disease
at a minimum. If the clinical trial endpoint requires the distinction
between RCB 2 and 3, or if the number of nodes involved will
determine the radiation treatment fields, then ALND would be
required for complete assessment of number of positive nodes.
CONCLUSION
Advances in the surgical management of the axilla have led to
changes in practice and more judicious use of ALND that may
minimize morbidity from surgery. From the viewpoint of drug
development, assessment of response to neoadjuvant chemother-
apy remains paramount, and appropriate assessment of residual
disease—the primary endpoint—is critical. Therefore minimizing
the FNR of axillary surgery to ensure more consistency in clinical
trial data, without mandating ALND for all patients is necessary.
The key elements to improve the accuracy of the assessment
include proper staging and identification of nodal involvement at
diagnosis, and appropriately targeted management of the axilla at
the time of surgical resection. The I-SPY2 trial team revised their
protocol, establishing requirements for surgeons treating patients
on the trial as outlined above, to maximize value of axillary
assessment, minimize surgical complications, enable modern
axillary management and prevent drop off in enrollment. At the
same time, standardizing the protocol helps maintain fidelity of
the primary endpoint and generate appropriate data to continue
to advance drug development. In the era of trials that promote a
precision medicine approach, we have made the appropriate
improvements to surgical management of the axilla and allow the
standards and treatment to evolve accordingly. These surgical
standards would be appropriate for neoadjuvant clinical trials with
pCR as endpoint and for clinical practice.
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